Asthma severity, burden and relationship with atopy among those with current asthma in Lima and Tumbes; Peru 2009–2010
| Asthma | Lima (n=84) | Tumbes (n=22) | p Value |
| Severity | 0.44 | ||
| Mild intermittent | 44 (52.4%) | 12 (54.5%) | |
| Mild persistent | 18 (21.4%) | 4 (18.2%) | |
| Moderate persistent | 18 (21.4%) | 3 (13.6%) | |
| Severe persistent | 4 (4.8%) | 3 (13.6%) | |
| Any emergency visits in the past 12 months | 24 (28.6%) | 10 (45.5%) | 0.21 |
| Rescue medication use | 34 (40.5%) | 10 (45.5%) | 0.86 |
| Never | 49 (58.3%) | 12 (54.5%) | |
| <1 use per week | 6 (7.1%) | 5 (22.3%) | |
| 1–3 uses per week | 14 (16.7%) | 3 (13.6%) | |
| >3 uses per week | 14 (16.7%) | 2 (9.1%) | |
| Any medication use in the past 12 months | 29 (31.1%) | 11 (50.0%) | 0.28 |
| Short-acting bronchodilator | 28 (33.3%) | 10 (45.5%) | 0.42 |
| Long-acting bronchodilator | 0 (0%) | 0 (0%) | 1 |
| Inhaled corticosteroid | 3 (3.6%) | 0 (0%) | 1 |
| Oral corticosteroid | 21 (25.0%) | 2 (9.1%) | 0.15 |
| Allergy and asthma | (n=614) | (n=630) | |
| Overall skin test positivity | 342 (55.7%) | 242 (38.4%) | <0.001 |
| Allergy in asthmatics | (n=84) | (n=22) | |
| Lifetime rhinitis symptoms | 45 (53.6%) | 13 (59.1%) | 0.83 |
| Lifetime eczema symptoms | 22 (26.2%) | 1 (4.5%) | 0.04 |
| Skin test positivity | (n=74) | (n=20) | |
| ≥1 | 57 (77.0%) | 11 (55.9%) | 0.09 |
| ≥2 | 46 (62.2%) | 7 (35.0%) | 0.06 |
| ≥3 | 30 (40.5%) | 4 (20.0%) | 0.12 |
| Allergy in non-asthmatics | (n=641) | (n=694) | |
| Lifetime rhinitis symptoms | 151 (23.2%) | 88 (12.7%) | <0.001 |
| Lifetime eczema symptoms | 107 (16.4%) | 15 (2.2%) | <0.001 |
| Skin test positivity | (n=540) | (n=610) | |
| ≥1 | 285 (52.8%) | 231 (37.9%) | <0.001 |
| ≥2 | 188 (34.8%) | 119 (19.5%) | <0.001 |
| ≥3 | 111 (21.1%) | 41 (6.7%) | <0.001 |